ANTI-IL-17F antibody

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Animals1

Outcomes

Angiogenesis

upin mice1

1 study

ANTI-IL-17F antibody increases angiogenesis in mice.
“neutralization of IL-17F promoted neovascularization and inhibited ischemic hindlimb muscle ECs' senescence and dysfunction.”
Animalsfollowing left femoral artery ligationhindlimb muscle
Interleukin-17F Induces Ischemic Injury in Aged Mice by Causing Endothelial Cells' Senescence and Dysfunction
FASEB journal : official publication of the Federation of American Societies for Experimental Biology7 Nov 2025

Latest

1 in 12 months

FASEB Journal7 Nov

Interleukin-17F Induces Ischemic Injury in Aged Mice by Causing Endothelial Cells' Senescence and Dysfunction

Experiments in miceInterventions

Paper

ANTI-IL-17F antibody

Outcomes

Latest

Interleukin-17F Induces Ischemic Injury in Aged Mice by Causing Endothelial Cells' Senescence and Dysfunction

Related